New NMOSD drug approved by the FDA
- Posted on: Jun 18 2020
- Leave a response
Inebilizumab (Uplizna) has been cleared for neuromyelitis optica spectrum disorder (NMOSD). The monotherapy drug is now the first and only B cell-depleting antibody approved for the disease.
Source: AAO
Posted in: Uncategorized
